Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Infectious Disease: COVID-19
Therapy: Thrombolytic Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients
In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2023 Category: Neurology Authors: Eman M Khedr, Ahmed Abdelwarith, Gehad M Moussa, Mostafa Saber Source Type: research
Safety and outcomes of intravenous thrombolytic therapy in ischemic stroke patients with COVID-19: CASCADE initiative
There is little information regarding the safety of intravenous tissue plasminogen activator (IV-tPA) in patients with stroke and COVID-19.
Source: Journal of Stroke and Cerebrovascular Diseases - September 19, 2021 Category: Neurology Authors: Payam Sasanejad, Leila Afshar Hezarkhani, Shahram Arsang-Jang, Georgios Tsivgoulis, Abdoreza Ghoreishi, Barlinn Kristian, Jan Rahmig, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Afshin Borhani-Haghighi, Payam Sariaslani, Athena Sharifi-Razavi, Kavian Ghandeh Source Type: research
